Company intelligence / Profile preview

Edusa Pharmaceuticals

United States

Ownership: Private
Development stage: Other

Overview

Edusa Pharmaceuticals developed several compounds targeting gastrointestinal and urological disorders. Its most advanced asset, pumosetrag (a serotonin receptor partial agonist), was in development for gastroesophageal reflux but appears to have been discontinued or stalled before approval. Other programs were also discontinued. There are no recent clinical results or ongoing trials.

Therapeutic areas: GastroenterologyUrologyNephrology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Edusa Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edusa Pharmaceuticals.

Explore the full profile